BRIEF-Cogent Biosciences Says FDA Accepts NDA With Priority Review For Bezuclastinib In Combination With Sunitinib

Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

0.00

May 28 (Reuters) - Cogent Biosciences Inc COGT.O:

  • ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW FOR BEZUCLASTINIB IN COMBINATION WITH SUNITINIB FOR PATIENTS WITH GIST

  • FDA GRANTS PRIORITY REVIEW TO NDA WITH PDUFA DATE NOVEMBER 30, 2026

  • FDA DOES NOT PLAN ADVISORY COMMITTEE OR IDENTIFY REVIEW ISSUES FOR NDA

Source text: ID:nGNXbWtVNw

Further company coverage: COGT.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.